Speaker



Marco Fossatelli | Country Manager BeNeLux & International DEI Lead, Alnylam Pharmaceuticals

Marco Fossatelli Country Manager Benelux of Boston based biotech company Alnylam Pharmaceuticals. He earned a PhD in Organic Chemistry at Utrecht University, igniting his interest in biotechnology. A long career in various operational and strategic roles in mid-sized and small pharmaceutical companies followed. He is now responsible for both overseeing the local operations in the Benelux (with now four life changing medicines launched) and site management of the Alnylam international office in Amsterdam. This office grew to 65 employees in less than 6 years and harbors a diverse group of people. In these roles he combines his scientific interest with a strong focus on people, as a company can only be successful with both a good technology and a good culture.  


Alnylam Pharmaceuticals

Alnylam has led the translation of RNAi (RNA interference) from Nobel Prize-winning discovery into an innovative, entirely new class of medicines. Founded in 2002 by a team of distinguished life sciences leaders, Alnylam’s vision is to harness the potential of RNAi therapeutics to transform the lives of people living with diseases for which there are limited or inadequate treatment options. Our pioneering work has delivered the world’s first and only approved RNAi therapeutics—ONPATTRO® (patisiran) in 2018, GIVLAARI® (givosiran) in 2019, OXLUMO® (lumasiran) in 2020, and AMVUTTRA® (vutrisiran) in 2022. We are advancing a deep pipeline of innovative RNAi-based medicines in four therapeutic areas: genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases.

Powered by:
Hyphen Projects   

Let's connect:           
Book a ticket
FAQ
Contact Us
Privacy Policy
Terms & Conditions 
Chamber of Commerce: 32110979
VAT no: NL8184.34.491.B01
          
 
 

                                    

Keep me informed Download our event app


© Copyright 2023 by Hyphen Projects